Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

BETHESDA, Md., April 01, 2024 -- Gain Therapeutics, Inc. , a clinical-stage biotechnology company leading the discovery and development of the next generation allosteric small molecule therapies,...

Related Keywords

Italy ,Switzerland ,Spain ,Swiss ,Elio Ambrosio ,Nic Johnson ,Jonas Hannestad ,Bristol Myers Squibb ,Matthias Alder ,Gain Therapeutics Inc ,Neuropsychiatric Institute ,Exchange Commission On ,Company Annual Report On Form ,Duke School Of Medicine ,Clinical Development At Alkahest ,University Of Oviedo ,European Union Horizon ,Michaelj Fox Foundation For Parkinson Research ,Compensation Committee Of Gain Board Directors ,Silverstein Foundation For Parkinson ,Nasdaq ,Linkedin ,University Of Messina ,Clinical Neuroscience Research Unit ,Swiss Innovation Agency ,Exchange Commission ,Yale School Of Medicine ,Chief Medical Officer ,Tranquis Therapeutics ,Capacity Bio ,Clinical Development ,Medical Director ,Denali Therapeutics ,Neuroscience Discovery Medicine ,Yale School ,Duke School ,Cell Biology ,Compensation Committee ,Gain Therapeutics ,Equity Incentive Plan ,Nasdaq Listing Rule ,Initial Vesting Date ,Silverstein Foundation ,Swiss Innovation ,Site Directed Enzyme Enhancement Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Markets ,